Hospital
Allina Health System
Allina Health System was paid $25.67M by Medicaid between Jan 2018 and Dec 2024, across 172 billing codes. Its largest line is 99284, emergency room visit (serious) — 37% of everything it billed.
33Billing provider infoALLINA HEALTH SYSTEM
SAINT PAUL, MN 55102
SAINT PAUL, MN 55102
33aNPI1457319485assigned 05/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.67M
24GClaims343,747
24DCodes billed172
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#11 of 36
Median peer was paid$11.46M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,723 | $1.88M | |
| 2019 | 43,600 | $3.51M | |
| 2020 | 39,081 | $3.15M | |
| 2021 | 43,009 | $3.16M | |
| 2022 | 74,917 | $5.72M | |
| 2023 | 61,773 | $4.87M | |
| 2024incomplete | 36,644 | $3.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 36,352 | 34,347 | $9.55M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 29,815 | 28,100 | $5.07M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.9% | 27,455 | 25,093 | $1.53M |
| 64450 | 4.8% | 2,111 | 934 | $1.24M | |
| 20553 | 2.8% | 4,622 | 3,003 | $713K | |
| 99152 | 2.1% | 11,724 | 8,342 | $534K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 2,315 | 2,021 | $521K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 1.5% | 5,779 | 1,041 | $394K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 16,074 | 14,375 | $380K |
| 64405 | 1.4% | 1,277 | 790 | $372K | |
| G0378 | Hospital observation service, per hour | 1.3% | 1,732 | 824 | $323K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 3,277 | 2,412 | $305K |
160 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,368 | $250K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,474 | $244K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,535 | $238K |
| 64400 | <1% | 175 | $217K | |
| H2012 | Behavioral health day treatment, per hour | <1% | 1,485 | $202K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,086 | $197K |
| Q3014 | Telehealth originating site facility fee | <1% | 6,591 | $188K |
| 80053 | Comprehensive metabolic panel | <1% | 5,542 | $178K |
| 85027 | <1% | 13,887 | $166K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,570 | $164K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,169 | $157K |
| 76818 | <1% | 795 | $127K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 753 | $122K |
| 64520 | <1% | 182 | $111K | |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 88 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,221 | $105K |
| 90870 | <1% | 430 | $99K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 810 | $81K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,424 | $81K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12,520 | $80K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,759 | $78K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 512 | $76K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,197 | $72K |
| 77003 | <1% | 950 | $69K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,415 | $67K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 11,439 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,574 | $63K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 236 | $61K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 780 | $57K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 376 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,921 | $55K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,743 | $45K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 321 | $44K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,005 | $36K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 388 | $35K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 530 | $33K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 259 | $32K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,436 | $32K |
| 99220 | <1% | 229 | $28K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 347 | $28K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,197 | $27K |
| 59025 | Fetal non-stress test | <1% | 513 | $26K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 63 | $26K |
| 97810 | <1% | 1,730 | $25K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 239 | $21K |
| 64615 | <1% | 78 | $21K | |
| 99254 | <1% | 187 | $21K | |
| 99226 | <1% | 259 | $18K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 348 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 513 | $17K |
| 81001 | <1% | 2,036 | $16K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,081 | $14K |
| 84484 | <1% | 3,712 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 123 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,613 | $11K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 227 | $11K |
| 99460 | <1% | 139 | $10K | |
| 99217 | <1% | 201 | $10K | |
| 82565 | <1% | 811 | $10K | |
| 99221 | <1% | 144 | $10K | |
| 97597 | <1% | 120 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,932 | $8K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 308 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 851 | $8K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 43 | $7K |
| 99253 | <1% | 99 | $7K | |
| 99255 | <1% | 54 | $7K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,694 | $7K |
| 97811 | <1% | 1,727 | $7K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 5,757 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 189 | $6K |
| 90901 | <1% | 210 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 59 | $6K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 93 | $6K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,891 | $6K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 74 | $6K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 279 | $6K |
| 62323 | <1% | 13 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 268 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,660 | $5K |
| 83690 | <1% | 1,433 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 189 | $5K |
| 76820 | <1% | 77 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 71 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 756 | $4K |
| 82248 | <1% | 1,223 | $4K | |
| 59514 | <1% | 39 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 450 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 190 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 44 | $4K |
| 99225 | <1% | 90 | $4K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 224 | $4K |
| 85610 | <1% | 1,314 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,443 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 889 | $3K |
| 81514 | <1% | 12 | $3K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 13 | $3K |
| 85018 | <1% | 777 | $3K | |
| 96376 | <1% | 220 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,357 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $3K |
| 83880 | <1% | 299 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,299 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 98 | $3K |
| 0240U | <1% | 26 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 268 | $2K |
| 87481 | <1% | 79 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 79 | $2K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $2K |
| 76825 | <1% | 15 | $2K | |
| 81025 | <1% | 356 | $2K | |
| 83735 | <1% | 735 | $2K | |
| 80061 | Lipid panel | <1% | 123 | $2K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 24 | $2K |
| 86803 | <1% | 128 | $2K | |
| 93226 | <1% | 27 | $2K | |
| 81003 | <1% | 292 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 13 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 70 | $2K |
| 86780 | <1% | 79 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $1K |
| 93227 | <1% | 74 | $1K | |
| 93016 | <1% | 59 | $931.69 | |
| 93325 | <1% | 84 | $873.09 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 379 | $872.59 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $742.50 |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 14 | $703.22 |
| 93018 | <1% | 64 | $660.39 | |
| 76937 | <1% | 27 | $634.91 | |
| 99462 | <1% | 19 | $609.71 | |
| C1769 | Guide wire | <1% | 138 | $516.97 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 48 | $508.97 |
| 83605 | <1% | 158 | $460.84 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12 | $442.54 |
| 97161 | <1% | 27 | $424.96 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 58 | $340.02 |
| 93228 | <1% | 15 | $323.40 | |
| 84703 | <1% | 58 | $308.86 | |
| 85379 | <1% | 28 | $307.10 | |
| 82077 | <1% | 56 | $299.03 | |
| 93321 | <1% | 57 | $294.41 | |
| 84145 | <1% | 16 | $264.88 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16 | $259.54 |
| 84132 | <1% | 115 | $220.19 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 103 | $218.57 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 80 | $216.20 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 36 | $167.04 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 42 | $140.41 |
| 95874 | <1% | 40 | $125.71 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 49 | $125.56 |
| 94060 | <1% | 14 | $110.31 | |
| 94729 | <1% | 15 | $101.34 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 25 | $90.52 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 126 | $70.73 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 69 | $68.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 38 | $47.07 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 56 | $20.95 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 15 | $11.85 |
| A9270 | Non-covered item or service | <1% | 1,987 | $2.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOSTREM, JILL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Allina Health System | Coon Rapids, MN | $48.83M |
| Allina Health System | Saint Paul, MN | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.